

1 **Knowledge, Attitudes and Demand Toward Cardiovascular Polygenic Risk Testing in Clinical**

2 **Practice: Cross-Sectional Survey of Patients**

3 Short title: Polygenic risk testing patient survey

4

5 Shanjot Brar, MD<sup>1\*</sup>, Jared Townsend, BSc<sup>1</sup>, Joban Phulka, MD<sup>1</sup>, Laura Halperin, MD<sup>1</sup>, Janet Liew,

6 BSc<sup>2</sup>, Jeremy Parker, PhD<sup>2</sup>, Liam R. Brunham, MD, PhD<sup>2,3</sup>, Zachary Laksman, MD<sup>2\*</sup>

7 1. Department of Medicine, University of British Columbia, Vancouver, Canada

8 2. Division of Cardiology, Department of Medicine, University of British Columbia,

9 Vancouver, Canada

10 3. Department of Medical Genetics, Centre for Heart Lung Innovation

11

12 \*Corresponding authors:

13 a. Shanjot Brar, MD

14 Gordon & Leslie Diamond Health Care Centre

15 2775 Laurel St, 9th Floor, Vancouver, BC, Canada V5Z1M9

16 Tel: 778-242-6293. Email: [shanjot@student.ubc.ca](mailto:shanjot@student.ubc.ca)

17 b. Zachary Laksman, MD (senior corresponding author)

18 1033 Davie St Suite 211, Vancouver, BC V6E 1M7

19 Tel: 604-806-8256. Email: [zlaksman@mail.ubc.ca](mailto:zlaksman@mail.ubc.ca)

20

21

22

23 **ABSTRACT**

24 **Background:**

25 The goal of this study was to assess patients' prior exposure and current level of knowledge of  
26 polygenic risk scores (PRSs). We also explored reactions to receiving a high-risk or low-risk  
27 score, and gauged the overall attitudes and demand patients have with regards to PRSs.

28 **Methods:**

29 We developed an online investigator-designed survey based on existing validated tools and  
30 previously designed surveys on genetic testing. There were two versions of the survey, one  
31 including a hypothetical high-risk PRS and one with a low-risk PRS. We administered the survey  
32 among patients attending a specialized cardiovascular prevention clinic.

33 **Results:**

34 A total of 226 participants responded to the survey. The study population was predominantly  
35 high-income earning, educated, and of European descent. 177 patients (79%) had never read or  
36 heard about polygenic testing. 209 patients (93%) had never discussed polygenic testing with  
37 their health care professional (HCP). 208 patients (93%) had never received polygenic testing.  
38 The average score on the knowledge quiz was 2.47/10 [95% C.I. (2.17, 2.78)]. Participants that  
39 received a high-risk survey scored 20.52/35 [95% C.I. (16.14, 24.9)] with regards to negative  
40 emotions while low-risk survey participants scored 17.96/35 [95% C.I. (13.98, 21.94)] ( $p<0.001$ ).  
41 Participants that received a high-risk survey scored 5.78/10 [95% C.I. (3.77, 7.79)] with regards  
42 to uncertainty and low-risk survey participants scored 4.34/10 [95% C.I. (2.50, 6.18)] ( $p<0.001$ ).  
43 Participants that received a high-risk survey scored 12.42/15 [95% C.I. (10.43, 14.41)] for  
44 demand and low-risk survey participants scored 12.22/15 [95% C.I. (9.66, 14.78)] ( $p=0.549$ ).

45 **Conclusions:**

46 Patients have limited prior exposure and knowledge of PRSs. Compared to receiving a low-risk  
47 score, participants receiving a high-risk score have more negative emotions and feelings of  
48 uncertainty. Despite the lack of knowledge, and the high rate of negative emotions and  
49 uncertainty, demand for PRSs in cardiology practice is high and expected to increase.

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67 **ABBREVIATIONS**

68 Non-standard Abbreviations and Acronyms:

69 PRS(s) - polygenic score(s)

70 AHA - American Heart Association

71 UBC – University of British Columbia

72 FACToR - Feelings About genomIc Testing Results

73 CAD – coronary artery disease

74 CAC – coronary artery calcium

75 CDC – Centres for Disease Control and Prevention

76 NIH – National Institutes of Health

77 DTC – direct to consumer

78

79

80

81

82

83

84

85

86

87

88

## 89 INTRODUCTION

90 Polygenic risk scores (PRSs) are being increasingly used to help predict diseases with complex  
91 inheritance patterns that have thus far not been explained by mendelian inheritance, such as  
92 atrial fibrillation and coronary artery disease.<sup>1,2</sup> PRSs also have the potential to contribute to  
93 the developing field of personalized medicine beyond risk prediction, and may inform  
94 personalized treatment strategies.<sup>3</sup> A recent American Heart Association (AHA) scientific  
95 statement explored the science, clinical considerations and future challenges of PRSs for  
96 cardiovascular disease and concluded that the addition of PRSs to clinical risk tools consistently  
97 enhances predictive ability.<sup>4</sup> There are many technical limitations to PRSs, however beyond this,  
98 the current workforce is not equipped to utilize PRSs in clinical practice due to insufficient  
99 knowledge, training, and tools.<sup>5</sup> Patients and consumers have minimal exposure and experience  
100 incorporating complex genomic information and probabilities into their decision making.<sup>6</sup>  
101 Studies have investigated patient responses to PRSs in other clinical diseases<sup>1,7,8</sup>, however such  
102 information is lacking in the cardiovascular space. Understanding these care gaps will help to  
103 inform future implementation strategies.

104

105 In this study, we directly tested the hypothesis that patients are poorly prepared to receive and  
106 integrate genetic results, including cardiovascular PRSs. To do this, we assessed patients' prior  
107 exposure and current level of knowledge of PRSs. We also explored patients' reactions to  
108 receiving a high-risk or low-risk result. Finally, we gauged the overall attitudes and demand  
109 patients have with regards to PRSs.

110

## 111 **METHODS**

112 We used an online survey with quantitative responses through the University of British  
113 Columbia (UBC) Survey tool (Supplemental Appendix). The UBC Survey tool is a Canadian-  
114 hosted program that is compliant with the British Columbia Freedom of Information and  
115 Protection Act. This project was approved by the UBC Research Ethics Board, REB# H22-02087.  
116 Initially, a consecutive chart review of patients that were attending at the St. Paul's Hospital  
117 Healthy Heart Program was conducted. The Healthy Heart Program is a quaternary referral  
118 centre located in Vancouver, British Columbia, which focuses on primary and secondary  
119 cardiovascular disease prevention. Patients that had previously consented to be contacted for  
120 research were identified from chart review. These patients were then individually contacted via  
121 phone call to consent to receive an email to participate. Patients who provided verbal consent  
122 were then individually sent an email which included a consent form and a link to the survey.  
123 Participants were randomly assigned 1:1 to receive either a high-risk or low-risk version of the  
124 survey. An example recruitment email is provided in the supplemental appendix.

125  
126 The survey design was based on existing validated tools and previously designed surveys on  
127 genetic testing<sup>1,7-13</sup> and was divided into the following components: a) Demographics, b) Prior  
128 knowledge, c) Knowledge of polygenic risk scores, d) Educational video e) Response toward a  
129 "high-risk" or "low-risk score" and f) Demand. Participant knowledge was assessed using a ten-  
130 question quiz, with a total score ranging from 0-10. The high-risk survey included an example of  
131 a polygenic risk score percentile of >95%, while the low-risk survey included an example of a  
132 polygenic risk score percentile <5%. The Feelings About genomic Testing Results (FACToR) scale

133 was adapted and used to assess participant reactions to high-risk and low-risk results.<sup>1</sup> Negative  
134 emotions were assessed using seven statements, with each statement being scored from a  
135 range of 0-5 (1 = Not at all, 5 = A great deal). Uncertainty was assessed using two statements  
136 with each statement being scored from a range of 1-5 (1 = Not at all, 5 = A great deal). A total  
137 score was then tabulated for both negative emotions (minimum = 7, maximum = 35) and  
138 uncertainty (minimum = 2, maximum = 10). A higher score indicated higher uncertainty, and  
139 more negative emotions. Participant demand for PRSs was assessed using three separate  
140 statements with each statement being scored from a range of 0-5 (1 = strongly disagree, 5 =  
141 strongly agree). A total score was then tabulated (minimum = 3, maximum = 15). A higher score  
142 indicated greater demand. The survey in its entirety, including both high-risk and low-risk  
143 examples, as well as the educational video are provided in the supplemental material.

144

## 145 **RESULTS**

146 A total of 1,756 patient charts were reviewed, of which 1,130 patients who had expressed  
147 interest in research participation were identified. These patients were individually contacted via  
148 telephone and 366 patients consented to participate in our survey. Half the participants were  
149 sent the high-risk survey (n=183) and half were sent the low-risk survey (n=183) via email. 118  
150 participants responded to the high-risk survey and 108 participants responded to the low-risk  
151 survey (Figure 1).

152

153 Participant characteristics including age, gender, highest level of education, household income  
154 and ethnicity are listed in Table 1. 177 patients (79%) had never read or heard about polygenic

155 risk scores. 209 patients (93%) had never discussed polygenic risk scores with their health care  
156 professional (HCP). 208 patients (93%) had never received polygenic risk score results (Figure  
157 2). The average score on the knowledge quiz was 2.47/10 [95% C.I. (2.17, 2.78)].  
158 Participants that received a high-risk survey scored 20.52/35 [95% C.I. (16.14, 24.9)] with  
159 regards to negative emotions while participants that received a low-risk survey scored 17.96/35  
160 [95% C.I. (13.98, 21.94)] ( $p < 0.001$ ). Participants that received a high-risk survey scored 5.78/10  
161 [95% C.I. (3.77, 7.79)] with regards to uncertainty while participants that received a low-risk  
162 survey scored 4.34/10 [95% C.I. (2.50, 6.18)] ( $p < 0.001$ ) (Table 2).

163  
164 Participant demand for PRS testing was high overall 12.32/15 [95% C.I. (11.99, 12.65)] and was  
165 not significantly different between individuals who received a high-risk survey 12.42/15 [95%  
166 C.I. (10.43, 14.41)] compared to a low-risk survey 12.22/15 [95% C.I. (9.66, 14.78)] ( $p = 0.549$ )  
167 (Table 3).

168

## 169 **DISCUSSION**

170 PRSs have a promising future application for identifying individuals at risk of cardiovascular  
171 disease and creating more individualized treatment plans, however, there are many technical  
172 and systematic limitations that must be overcome prior to their inclusion in routine  
173 cardiovascular care.<sup>2,4</sup> As these limitations are overcome, and PRSs are used more regularly in  
174 routine care, it is increasingly important that we understand patient perspectives as we train  
175 our future workforce and develop implementation strategies across different health systems.  
176 Previous studies have investigated patient responses to PRSs in other clinical diseases<sup>1,7,8</sup>,



177 however to our knowledge, this is the first study examining patient perspectives in the  
178 cardiovascular space.

179  
180 One of the proposed goals of PRSs in clinical practice is to use genetic based risk as a means of  
181 promoting healthy behaviours and motivating high risk individuals to make lifestyle  
182 changes.<sup>4,6,15,16</sup> Numerous studies however have failed to show a change in patient behaviour  
183 by communicating genetic risk.<sup>17-19</sup> Knowles et. al. demonstrated no major effect of  
184 communicating a genetic risk score for CAD in reducing certain health risk behaviours.<sup>20</sup>  
185 Conversely, studies have shown behaviour modification associated with patients who  
186 underwent coronary artery calcium (CAC) testing.<sup>21,22</sup> Although patients' behavioural response  
187 to genetic risk is influenced by multiple factors, a significant barrier includes patients'  
188 understanding and interpretation of genetic risk.<sup>16,23,24</sup> Many authors have suggested that  
189 patients' understanding of cardiovascular PRSs is poor.<sup>25</sup> Our study confirms this finding and  
190 despite the education level of our surveyed patients, 177 patients (79%) had never read or  
191 heard about polygenic testing, and the average score on the knowledge quiz was 2.47/10  
192 (24.7%). Moreover, the survey population was selected from a group of patients already  
193 followed at a sub-specialized cardiovascular disease prevention clinic, and an even lower level  
194 of exposure and knowledge would be expected if this survey was offered to a broader and  
195 more diverse population.

196 Genetics related literacy impacts the value patients place on genetic information as well as how  
197 patients evaluate the utility of genetic testing.<sup>13,26</sup> Low genetic literacy has also been associated  
198 with poor understanding of the limitations of genetic testing.<sup>27</sup> This implies that a low

199 knowledge of genetic testing, as seen in our study, would result in a significant risk of  
200 misinterpretation or misapplication of genetic risk scoring. Although this phenomenon has not  
201 been explicitly reported in the cardiovascular space, it is well documented in other clinical fields  
202 that integrate genetic testing.<sup>12,27</sup> It is unclear, the level of knowledge or the methods of  
203 knowledge translation that are required for the clinical implementation of cardiovascular PRSs,  
204 and further understanding of this topic is needed. Furthermore, it has already been identified  
205 both by the CDC and the NIH that the current workforce of clinicians and health care providers  
206 are undertrained and poorly suited to provide the requisite education regarding complex  
207 probabilistic polygenic testing.<sup>28,29</sup>

208  
209 Our results also demonstrate that patients given a high-risk PRS report higher levels of negative  
210 emotions and uncertainty about PRSs than those who received a low-risk PRS. This was an  
211 expected finding, as previous studies have shown, that patients will often perceive health data  
212 as threats and the recommended behavioural change will be quite different from their health  
213 care provider.<sup>23</sup> This finding is seen even more commonly when it is related to genetic  
214 information.<sup>30,31</sup> This demonstrates a dilemma for clinicians and health care providers as  
215 patients with high-risk PRS will likely require more intensive risk modifying treatment plans and  
216 closer monitoring but may also have a significant amount of uncertainty and negative emotions  
217 to overcome. Previous studies have shown that patient interpretation of genetic risk  
218 information is not only related to the statistical findings, but also to patients' uncertainties  
219 related to the topic.<sup>32,33</sup> The higher degree of uncertainty and negative emotions will be an  
220 obstacle for clinical implementation and must be accounted for in future integration of PRSs.

221

222 Despite the high level of negative emotions and uncertainty, surveyed patients reported that  
223 the health benefits of PRS outweigh the risks (79.6% responded agree or strongly agree) and  
224 believe that polygenic testing should be included in heart disease prevention programs for the  
225 general public (81.9% responded agree or strongly agree). Furthermore, surveyed patients  
226 reported that they would like PRS included in their care plans (85.3% responded agree or  
227 strongly agree). Taken together, this suggests a high demand for use of PRSs in clinical practice.  
228 This trend was demonstrated across all participant groups, regardless of whether they received  
229 a high-risk score, or a low-risk score. These findings were expected, as a demand for genetic  
230 testing in the general population is high, as exemplified by the estimated 26 million people that  
231 had used online direct-to-consumer (DTC) genetic testing by the end of 2018.<sup>15</sup> A high demand  
232 for PRSs is a promising finding for the future implementation of PRSs, however as highlighted  
233 above, the majority of patients have poor knowledge and understanding of PRSs, and thus the  
234 potential for misapplication remains quite high.

235

236 The future of PRSs includes a potential for individualized screening, preventative measures, and  
237 pharmacotherapy. This brings a slew of challenges for clinicians and health care providers,  
238 including how to determine the best ways to communicate the science. Guidelines on how to  
239 navigate communication of genetic information to patients with cardiovascular disease such as  
240 inherited rhythm disorders, hypertrophic cardiomyopathy and familial hypercholesteremia  
241 exist, however such guidelines are lacking for PRSs.<sup>34,35</sup> Importantly clinicians must be able to  
242 effectively communicate the benefits, risk and limitations of PRSs.<sup>6</sup> There is clinical need to

243 develop educational materials for both patients and guidelines for clinicians on how to convey  
244 this information. Knowledge translation in PRSs will be a great challenge moving forward,  
245 however there are many evidence-based strategies that exists for the presentation of genetic  
246 risk.<sup>36,37</sup> Incorporating these lessons to PRSs will be pivotal to ensure patients understand and  
247 can effectively engage in their care. Lessons can also be learned from shared decision making  
248 tools in the cardiovascular space, such as tools to help guide patient centered conversations  
249 about anticoagulation in atrial fibrillation.<sup>38</sup> Previous studies have shown that such shared  
250 decision making tools can significantly lower decisional conflict between patients and  
251 clinicians.<sup>39</sup> Development of similar tools for PRSs would potentially enhance patient and  
252 physician experience with navigating discussion and implementation of PRSs.

253

## 254 **Limitations**

255 Our study has important limitations, largely related to the selection of our patient population.  
256 The study population was predominantly high-income earning, educated, and of European  
257 descent. As our survey required consent at two different stages prior to distribution of the  
258 survey, this specific population is likely a result of selection bias and may indicate that this  
259 specific population is more interested in PRSs. This would need further investigation, however  
260 would contribute to the growing concern regarding widening care disparities related to PRSs.<sup>14</sup>  
261 Further, our method of accessing patients was through a specialized cardiovascular disease  
262 prevention clinic where patient attendance likely indicates their want, or need, to make risk  
263 factor modifications. This would result in significant selection bias and not necessarily represent  
264 a routine cardiology clinic. Additionally, we accessed patients that had already consented to

265 research involvement due to the process of ethical approval. As such these patients are likely  
266 highly engaged in their care and may not represent the patient population in contemporary  
267 clinical practice.

## 268 **Conclusions**

269 Patients attending a specialized cardiovascular clinic focused on primary and secondary  
270 prevention had limited prior exposure and knowledge with regards to PRSs. When compared to  
271 receiving a low-risk score, participants that receive a high-risk score have more negative  
272 emotions and feelings of uncertainty. Despite the lack of knowledge, and the high rate of  
273 negative emotions and uncertainty, patient demand for PRSs in contemporary cardiology  
274 practice is high. The analytical aspects of PRSs are continually being addressed, however there  
275 needs to be concurrent focus on improving patient and provider exposure and knowledge to  
276 avoid future harm. Future studies should focus on the development of educational materials  
277 and guidelines to address the barriers brought forward by this study.

278

## 279 **SOURCE OF FUNDING**

280 This research did not receive any specific grant from funding agencies in the public, commercial,  
281 or not-for-profit sectors.

282

## 283 **DISCLOSURES**

284 The authors have no conflicts to disclose.

285

286

287 **REFERENCES**

- 288 1. Peck L, Borle K, Folkersen L, Austin J. Why do people seek out polygenic risk scores for  
289 complex disorders, and how do they understand and react to results? *European Journal of*  
290 *Human Genetics*. 2022;30(1):81–87.
- 291 2. Phulka JS, Ashraf M, Bajwa BK, Pare G, Laksman Z. Current State and Future of Polygenic  
292 Risk Scores in Cardiometabolic Disease: A Scoping Review. *Circulation: Genomic and Precision*  
293 *Medicine*. 2023;16(3):286–313.
- 294 3. Yang S, Zhou X. Accurate and Scalable Construction of Polygenic Scores in Large Biobank  
295 Data Sets. *The American Journal of Human Genetics*. 2020;106(5):679–693.
- 296 4. O’Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, O’Donnell  
297 CJ, Willer CJ, Natarajan P, on behalf of the American Heart Association Council on Genomic and  
298 Precision Medicine; Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and  
299 Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and  
300 Cardiometabolic Health; and Council on Peripheral Vascular Disease. Polygenic Risk Scores for  
301 Cardiovascular Disease: A Scientific Statement From the American Heart Association.  
302 *Circulation*. 2022;146(8).
- 303 5. Haga SB, Kim E, Myers RA, Ginsburg GS. Primary Care Physicians’ Knowledge, Attitudes, and  
304 Experience with Personal Genetic Testing. *Journal of Personalized Medicine*. 2019;9(2):29.
- 305 6. Slunecka JL, Van Der Zee MD, Beck JJ, Johnson BN, Finnicum CT, Pool R, Hottenga J-J, De  
306 Geus EJC, Ehli EA. Implementation and implications for polygenic risk scores in healthcare.  
307 *Human Genomics*. 2021;15(1):46.

- 308 7. Suckiel SA, Braganza GT, Aguiñiga KL, Odgis JA, Bonini KE, Kenny EE, Hamilton JG, Abul-Husn  
309 NS. Perspectives of diverse Spanish- and English-speaking patients on the clinical use of  
310 polygenic risk scores. *Genetics in Medicine*. 2022;24(6):1217–1226.
- 311 8. Hollitt GL, Siggs OM, Ridge B, Keane MC, Mackey DA, MacGregor S, Hewitt AW, Craig JE,  
312 Souzeau E. Attitudes Towards Polygenic Risk Testing in Individuals with Glaucoma.  
313 *Ophthalmology Glaucoma*. 2021:S2589419621002635.
- 314 9. Saya S, McIntosh JG, Winship IM, Milton S, Clendenning M, Kyriakides M, Oberoi J,  
315 Buchanan DD, Jenkins MA, Emery JD. Informed choice and attitudes regarding a genomic test to  
316 predict risk of colorectal cancer in general practice. *Patient Education and Counseling*.  
317 2022;105(4):987–995.
- 318 10. Smit AK, Sharman AR, Espinoza D, Wallingford C, Young M, Dunlop K, Tiller J, Newson AJ,  
319 Meiser B, Cust AE, Yanes T. Knowledge, views and expectations for cancer polygenic risk testing  
320 in clinical practice: A cross-sectional survey of health professionals. *Clinical Genetics*.  
321 2021;100(4):430–439.
- 322 11. Scherr CL, Kalke K, Ramesh S, Fakhari H, Dellefave-Castillo LM, Smith ME, Kalny C, McNally  
323 EM, Rasmussen-Torvik LJ. Integrating clinical genetics in cardiology: Current practices and  
324 recommendations for education. *Genetics in Medicine*. 2022;24(5):1054–1061.
- 325 12. Haga SB, Barry WT, Mills R, Ginsburg GS, Svetkey L, Sullivan J, Willard HF. Public Knowledge  
326 of and Attitudes Toward Genetics and Genetic Testing. *Genetic Testing and Molecular*  
327 *Biomarkers*. 2013;17(4):327–335.
- 328 13. Kaphingst KA, Blanchard M, Milam L, Pokharel M, Elrick A, Goodman MS. Relationships  
329 Between Health Literacy and Genomics-Related Knowledge, Self-Efficacy, Perceived

- 330 Importance, and Communication in a Medically Underserved Population. *Journal of Health*  
331 *Communication*. 2016;21(sup1):58–68.
- 332 14. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current  
333 polygenic risk scores may exacerbate health disparities. *Nature Genetics*. 2019;51(4):584–591.
- 334 15. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments.  
335 *Genome Medicine*. 2020;12(1):44.
- 336 16. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk  
337 scores. *Nature Reviews Genetics*. 2018;19(9):581–590.
- 338 17. Weinberg DS, Myers RE, Keenan E, Ruth K, Sifri R, Ziring B, Ross E, Manne SL. Genetic and  
339 Environmental Risk Assessment and Colorectal Cancer Screening in an Average-Risk Population:  
340 A Randomized Trial. *Annals of Internal Medicine*. 2014;161(8):537.
- 341 18. Silarova B, Sharp S, Usher-Smith JA, Lucas J, Payne RA, Shefer G, Moore C, Girling C,  
342 Lawrence K, Tolkien Z, Walker M, Butterworth A, Di Angelantonio E, Danesh J, Griffin SJ. Effect  
343 of communicating phenotypic and genetic risk of coronary heart disease alongside web-based  
344 lifestyle advice: the INFORM Randomised Controlled Trial. *Heart*. 2019;105(13):982–989.
- 345 19. Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, Marteau TM. The impact of  
346 communicating genetic risks of disease on risk-reducing health behaviour: systematic review  
347 with meta-analysis. *BMJ*. 2016:i1102.
- 348 20. Knowles JW, Zarafshar S, Pavlovic A, Goldstein BA, Tsai S, Li J, McConnell MV, Absher D,  
349 Ashley EA, Kiernan M, Ioannidis JPA, Assimes TL. Impact of a Genetic Risk Score for Coronary  
350 Artery Disease on Reducing Cardiovascular Risk: A Pilot Randomized Controlled Study. *Frontiers*  
351 *in Cardiovascular Medicine*. 2017;4:53.



- 352 21. Kalia NK, Cespedes L, Youssef G, Li D, Budoff MJ. Motivational effects of coronary artery  
353 calcium scores on statin adherence and weight loss. *Coronary Artery Disease*. 2015;26(3):225–  
354 230.
- 355 22. Mamudu HM, Paul TK, Veeranki SP, Budoff M. The effects of coronary artery calcium  
356 screening on behavioral modification, risk perception, and medication adherence among  
357 asymptomatic adults: A systematic review. *Atherosclerosis*. 2014;236(2):338–350.
- 358 23. Marteau TM, Weinman J. Self-regulation and the behavioural response to DNA risk  
359 information: A theoretical analysis and framework for future research. *Social Science &*  
360 *Medicine*. 2006;62(6):1360–1368.
- 361 24. Austin J. The effect of genetic test-based risk information on behavioral outcomes: A critical  
362 examination of failed trials and a call to action. *American Journal of Medical Genetics Part A*.  
363 2015;167(12):2913–2915.
- 364 25. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease.  
365 *Nature Reviews Cardiology*. 2022;19(5):291–301.
- 366 26. Hooker GW, Peay H, Erby L, Bayless T, Biesecker BB, Roter DL. Genetic literacy and patient  
367 perceptions of IBD testing utility and disease control: a randomized vignette study of genetic  
368 testing. *Inflammatory Bowel Diseases*. 2014;20(5):901–908.
- 369 27. Milo Rasouly H, Cuneo N, Marasa M, DeMaria N, Chatterjee D, Thompson JJ, Fasel DA,  
370 Wynn J, Chung WK, Appelbaum P, Weng C, Bakken S, Gharavi AG. GeneLiFT: A novel test to  
371 facilitate rapid screening of genetic literacy in a diverse population undergoing genetic testing.  
372 *Journal of Genetic Counseling*. 2021;30(3):742–754.

- 373 28. Osei, Jeffery. Polygenic Risk Scores in Clinical Practice? Still Making the Case. *Genomic and*  
374 *Precision Health*.
- 375 29. Wand H, Lambert SA, Tamburro C, Iacocca MA, O’Sullivan JW, Sillari C, Kullo IJ, Rowley R,  
376 Dron JS, Brockman D, Venner E, McCarthy MI, Antoniou AC, Easton DF, Hegele RA, et al.  
377 Improving reporting standards for polygenic scores in risk prediction studies. *Nature*.  
378 2021;591(7849):211–219.
- 379 30. Prior L, Wood F, Gray J, Pill R, Hughes D. Making risk visible: The role of images in the  
380 assessment of (cancer) genetic risk. *Health, Risk & Society*. 2002;4(3):241–258.
- 381 31. Walter FM. Lay Understanding of Familial Risk of Common Chronic Diseases: A Systematic  
382 Review and Synthesis of Qualitative Research. *The Annals of Family Medicine*. 2004;2(6):583–  
383 594.
- 384 32. Wöhlke S, Schaper M, Schicktanz S. How Uncertainty Influences Lay People’s Attitudes and  
385 Risk Perceptions Concerning Predictive Genetic Testing and Risk Communication. *Frontiers in*  
386 *Genetics*. 2019;10:380.
- 387 33. Engelhardt EG, Pieterse AH, Han PKJ, Van Duijn-Bakker N, Cluitmans F, Maartense E, Bos  
388 MMEM, Weijl NI, Punt CJA, Quarles Van Ufford-Mannesse P, Sleeboom H, Portielje JEA, Van Der  
389 Hoeven KJM, Woei-A-Jin FJS, Kroep JR, et al. Disclosing the Uncertainty Associated with  
390 Prognostic Estimates in Breast Cancer: Current Practices and Patients’ Perceptions of  
391 Uncertainty. *Medical Decision Making*. 2017;37(3):179–192.
- 392 34. Burns C, James C, Ingles J. Communication of genetic information to families with inherited  
393 rhythm disorders. *Heart Rhythm*. 2018;15(5):780–786.

- 394 35. Platt J. A Person-Centered Approach to Cardiovascular Genetic Testing. *Cold Spring Harbor*  
395 *Perspectives in Medicine*. 2020;10(7):a036624.
- 396 36. Lautenbach DM, Christensen KD, Sparks JA, Green RC. Communicating genetic risk  
397 information for common disorders in the era of genomic medicine. *Annual Review of Genomics*  
398 *and Human Genetics*. 2013;14:491–513.
- 399 37. Hamilton KV, Fox LC, Nichols KE. How I Communicate with Patients and Families about  
400 Germline Genetic Information. *Blood*. 2023:blood.2022017379.
- 401 38. Eckman MH, Wise RE, Naylor K, Arduser L, Lip GYH, Kissela B, Flaherty M, Kleindorfer D,  
402 Khan F, Schauer DP, Kues J, Costea A. Developing an Atrial Fibrillation Guideline Support Tool  
403 (AFGuST) for shared decision making. *Current Medical Research and Opinion*. 2015;31(4):603–  
404 614.
- 405 39. Wang PJ, Lu Y, Mahaffey KW, Lin A, Morin DP, Sears SF, Chung MK, Russo AM, Lin B, Piccini  
406 J, Hills MT, Berube C, Pundi K, Baykaner T, Garay G, et al. Randomized Clinical Trial to Evaluate  
407 an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway. *Journal of the*  
408 *American Heart Association*. 2023;12(3):e028562.
- 409  
410  
411  
412  
413  
414  
415

416 **TABLES**

417 **Table 1. Patient demographics.**

|                                   |          |
|-----------------------------------|----------|
| Age, n (%)                        |          |
| 18-30 years                       | 5 (2)    |
| 31-40 years                       | 10 (4)   |
| 41-50 years                       | 27 (12)  |
| 51-60 years                       | 57 (25)  |
| >60 years                         | 127 (56) |
| Gender, n (%)                     |          |
| Male                              | 121 (54) |
| Female                            | 105 (46) |
| Highest level of education, n (%) |          |
| Did not Finish High School        | 6 (3)    |
| High School                       | 27 (12)  |
| Post-Secondary                    | 77 (34)  |
| Bachelor's Degree                 | 77 (34)  |
| Master's Degree                   | 21 (9)   |
| Doctorate/PhD                     | 18 (8)   |
| Household income, n (%)           |          |
| <\$50,000                         | 37 (16)  |
| \$50,000 – \$150,000              | 110 (49) |
| >\$150,000                        | 79 (35)  |
| Ethnicity, n (%)                  |          |
| African                           | 1 (0)    |
| European                          | 155 (69) |
| East Asian                        | 15 (7)   |
| South Asian                       | 11 (5)   |
| Southeast Asian                   | 6 (3)    |
| First Nations/Indigenous          | 2 (1)    |
| Hispanic                          | 1 (0)    |
| Middle Eastern                    | 2 (1)    |
| Other                             | 33 (15)  |

418

419

420

421

422

423

424

425 **Table 2. Participant negative emotions and uncertainty scores for polygenic risk scores.**

|                               | High Risk           | Low Risk            | P value          |
|-------------------------------|---------------------|---------------------|------------------|
|                               | N = 118             | N = 108             |                  |
| <b>Negative Emotion</b>       |                     |                     |                  |
| <b>Total Score (/35) ± SD</b> | <b>20.52 ± 4.38</b> | <b>17.96 ± 3.98</b> | <b>&lt;0.001</b> |
| <b>Uncertainty</b>            |                     |                     |                  |
| <b>Total Score (/10) ± SD</b> | <b>5.78 ± 2.01</b>  | <b>4.34 ± 1.84</b>  | <b>&lt;0.001</b> |

426

427 **Table 3. Participant demand for polygenic risk scores.**

|                               | High Risk           | Low Risk            | P value      |
|-------------------------------|---------------------|---------------------|--------------|
|                               | N = 118             | N = 108             |              |
| <b>Belief</b>                 |                     |                     |              |
| <b>Total Score (/15) ± SD</b> | <b>12.42 ± 1.99</b> | <b>12.22 ± 2.56</b> | <b>0.549</b> |

428

429

430

431

432

433

434


435

436

437

438

439 **FIGURES**



455 **Figure 1. Study enrollment**

456


457

458

459

460

461



462

|  | Yes, n (%)     | No, n (%)       |
|--|----------------|-----------------|
| <b>A. Have you ever read or heard about polygenic testing?</b>   | <b>47 (21)</b> | <b>177 (79)</b> |
| <b>B. Have you ever discussed polygenic testing with an HCP?</b> | <b>15 (7)</b>  | <b>209 (93)</b> |
| <b>C. Have you ever received polygenic testing?</b>              | <b>16 (7)</b>  | <b>208 (93)</b> |

463 **Figure 2. Participant prior knowledge of Polygenic Risk Scores (PRS)**

464

465 **SUPPLEMENTAL MATERIAL**

466 Material attached separately.